PMID- 30641006
OWN - NLM
STAT- MEDLINE
DCOM- 20190218
LR  - 20190219
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 36
IP  - 10
DP  - 2016 Oct
TI  - [Efficacy of Hebi Formula Combined Methotrexate on Early Rheumatoid Arthritis 
      Patients with Dis- harmony of Gan and Pi Syndrome and Its Effects on Serum MMP-3 
      and RANK/RANKL/OPG Expressions].
PG  - 1197-1201
AB  - Objective To observe the efficacy of Hebi Formula (HF) combined Methotrexate 
      (MTX) on early rheumatoid arthritis (RA) patients with disharmony of Gan and Pi 
      syndrome (DGPS) and its effects on matrix metalloproteinase-3 (MMP-3) activator 
      of nuclear factor-KB/receptor activator of nu- clear factor-KB/osteoprotegerin 
      (RANK/RANKL/OPG). Methods Totally 72 early RA patients with DGPS were assigned to 
      the treatment group and the control group according to random digit table, 36 in 
      each group. Patients in the control group took MTX, while those in the treatment 
      group additionally took HF. MTX dose was increased from 7. 5 mg to 12. 5 mg 
      gradually, once per week, and the course of treatment was 24 weeks. Efficacy for 
      Chinese medicine (CM) syndromes, ACR20 improvement rate, laboratory re- lated 
      indices [ rheumatoid factor ( RF ) , erythrocyte sedimentation rate ( ESR ) , 
      C-reactive protein (CRP) , anti-cyclic citrullinated peptide antibody (CCP)], 
      serum levels of MMP-3, OPG, RANKL, and adverse reactions were observed. Results 
      The standard arriving rate of ACR20 was 82. 86% (2935) in the treatment group, 
      higher than that in the control group [51. 52% (173) ;P <0. 05). The effective 
      rate of CM syndrome was 85. 7% (30f35) in the treatment group, higher than that 
      in the control group [63. 6% (21/33) ;P <0. 05). Compared with before treatment 
      in the same group, levels of RF,ESR,CRP,MMP-3, and RANKL decreased, the OPG level 
      increased in the two groups after treatment (P <0. 05, P <0. 01). Compared with 
      the control group, levels of RF, ESR, CRP, and RANKL all decreased with 
      statistical difference (P <0. 01 , P <0. 05). Liver dysfunction occurred in 1 
      case of the treatment group. Leucopenia occurred in 1 case and liver dysfunction 
      occurred in 2 cases of the control group. Conclusion HF com- bined MTX could 
      improve symptoms of early RA patients with DGPS, and regulate bone destruction 
      in- duced by RANK/RANKL/OPG systems.
FAU - Zhang, Yan-Yan
AU  - Zhang YY
FAU - Wang, Jian
AU  - Wang J
FAU - Jiang, Ping
AU  - Jiang P
FAU - Wu, Ji-Biao
AU  - Wu JB
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Osteoprotegerin)
RN  - 0 (RANK Ligand)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Blood Sedimentation
MH  - *Drugs, Chinese Herbal/therapeutic use
MH  - Humans
MH  - Matrix Metalloproteinase 3/metabolism
MH  - *Methotrexate/therapeutic use
MH  - Osteoprotegerin
MH  - RANK Ligand
MH  - Rheumatoid Factor
MH  - Syndrome
EDAT- 2016/10/01 00:00
MHDA- 2016/10/01 00:01
CRDT- 2019/01/15 06:00
PHST- 2019/01/15 06:00 [entrez]
PHST- 2016/10/01 00:00 [pubmed]
PHST- 2016/10/01 00:01 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Oct;36(10):1197-1201.